Skye Bioscience, Inc. (SKYE) Financial Statements (2024 and earlier)

Company Profile

Business Address 11250 EL CAMINO REAL, SUITE 100
SAN DIEGO, CA 92130
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,244,5278,983,0072,469,4101,829,9771,853,373259,955
Cash and cash equivalents1,244,5278,983,0072,469,4101,829,9771,853,373259,955
Restricted cash and investments4,5804,5714,5664,5384,5124,428
Receivables 13,432    
Prepaid expense850,377554,217190,134152,69593,193291,428
Disposal group, including discontinued operation 6,432,216     
Other current assets412,01856,8702757,5502,609 
Other undisclosed current assets      
Total current assets:8,943,7189,612,0972,664,3851,994,7601,953,687555,811
Noncurrent Assets
Operating lease, right-of-use asset71,191146,972  
Property, plant and equipment87,85487,7107,3411,9833,4451,407
Other noncurrent assets8,3098,309    
Total noncurrent assets:167,354242,9917,3411,9833,4451,407
TOTAL ASSETS:9,111,0729,855,0882,671,7261,996,7431,957,132557,218
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,327,7311,242,330364,340129,809200,058299,259
Employee-related liabilities344,450  66,21354,512
Accounts payable1,669,997897,880364,340129,80915,597100,921
Accrued liabilities657,734   118,248143,826
Debt1,848,3751,974,90564,062  235,000
Derivative instruments and hedges, liabilities 359,73238,567410,60315,738,913 
Due to related parties220,7512,13017,03210,000  
Other liabilities1,422,442375,842259,111420,406  
Other undisclosed current liabilities6,299,824257,28344,087  271,715
Total current liabilities:12,119,1263,912,222787,199970,81815,938,971805,974
Noncurrent Liabilities
Long-term debt and lease obligation  78,7001,433,741387,0701,360,960 
Long-term debt, excluding current maturities   1,433,741387,0701,360,960 
Liabilities, other than long-term debt   90,797219,453551,322
Operating lease, liability 78,700  
Derivative instruments and hedges, liabilities    90,797219,453551,322
Other undisclosed noncurrent liabilities  (78,700)    
Total noncurrent liabilities: 78,7001,433,741477,8671,580,413551,322
Total liabilities:12,119,1263,990,9222,220,9401,448,68517,519,3841,357,296
Equity
Equity, attributable to parent(3,008,054)5,864,166450,786548,058(15,562,252)(3,569,506)
Common stock913,528476,108288,074182,895133,90833,623
Additional paid in capital62,816,18352,644,22138,896,69332,538,44516,230,9569,444,831
Accumulated deficit(66,737,765)(47,256,163)(38,733,981)(32,173,282)(33,225,107)(14,030,871)
Warrants and rights outstanding     1,297,991982,911
Other undisclosed equity      2,769,428
Total equity:(3,008,054)5,864,166450,786548,058(15,562,252)(800,078)
TOTAL LIABILITIES AND EQUITY:9,111,0729,855,0882,671,7261,996,7431,957,132557,218

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Operating expenses(18,311,732)(7,847,714)(6,289,013)(6,632,578)(4,692,523)(3,859,229)
Operating loss:(18,311,732)(7,847,714)(6,289,013)(6,632,578)(4,692,523)(3,859,229)
Nonoperating income (expense)(1,163,129)(672,368)(270,086)7,686,00384 
Investment income, nonoperating19,0113292684 
Interest and debt expense(665,133)117,953(706,385)(725,425)(685,155)(667)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   706,385725,425(13,815,000)767,198
Income (loss) from continuing operations before equity method investments, income taxes:(20,139,994)(8,402,129)(6,559,099)1,053,425(19,192,594)(3,092,698)
Other undisclosed income (loss) from continuing operations before income taxes665,133(117,953)    
Income (loss) from continuing operations before income taxes:(19,474,861)(8,520,082)(6,559,099)1,053,425(19,192,594)(3,092,698)
Income tax expense(6,741)(2,100)(1,600)(1,600)(1,642)(1,600)
Income (loss) from continuing operations:(19,481,602)(8,522,182)(6,560,699)1,051,825(19,194,236)(3,094,298)
Income (loss) before gain (loss) on sale of properties:(8,522,182)(6,560,699)1,051,825(19,194,236)(3,094,298)
Net income (loss) attributable to parent:(19,481,602)(8,522,182)(6,560,699)1,051,825(19,194,236)(3,094,298)
Preferred stock dividends and other adjustments      (1,044,000)
Net income (loss) available to common stockholders, diluted:(19,481,602)(8,522,182)(6,560,699)1,051,825(19,194,236)(4,138,298)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(19,481,602)(8,522,182)(6,560,699)1,051,825(19,194,236)(3,094,298)
Comprehensive income (loss), net of tax, attributable to parent:(19,481,602)(8,522,182)(6,560,699)1,051,825(19,194,236)(3,094,298)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: